特发性肺纤维化的治疗
Treatment of Idiopathic Pulmonary Fibrosis.
作者信息
Abuserewa Sherif T, Duff Richard, Becker Gregory
机构信息
Internal Medicine, Grand Strand Regional Medical Center, Myrtle Beach, USA.
Department of Pulmonary and Critical Care Medicine, Grand Strand Medical Center, Myrtle Beach, USA.
出版信息
Cureus. 2021 May 31;13(5):e15360. doi: 10.7759/cureus.15360. eCollection 2021 May.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to anti-inflammatory therapies and the prognosis remains poor. In this review of literature, we will be focusing on main lines of treatment including current medications, supportive care, lung transplantation evaluation, and potential future strategies of treatment.
摘要
特发性肺纤维化（IPF）是一种病因不明的慢性、进行性、纤维化间质性肺炎，发生于成年人且局限于肺部。过去，治疗旨在尽量减少炎症并减缓炎症向纤维化的进展。然而，IPF的潜在病变可能纤维化程度高于炎症程度，这就解释了为什么很少有患者对抗炎治疗有反应且预后仍然很差。在这篇文献综述中，我们将重点关注主要治疗方法，包括目前的药物治疗、支持治疗、肺移植评估以及未来潜在的治疗策略。
相似文献
1
Treatment of Idiopathic Pulmonary Fibrosis.特发性肺纤维化的治疗
Cureus. 2021 May 31;13(5):e15360. doi: 10.7759/cureus.15360. eCollection 2021 May.
2
Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management.特发性肺纤维化的合并症：识别与管理
Front Med (Lausanne). 2017 Aug 2;4:123. doi: 10.3389/fmed.2017.00123. eCollection 2017.
3
S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.BALF 中的 S100A9 是特发性肺纤维化的候选生物标志物。
Respir Med. 2012 Apr;106(4):571-80. doi: 10.1016/j.rmed.2011.12.010. Epub 2011 Dec 30.
4
What We Know About the Pathogenesis of Idiopathic Pulmonary Fibrosis.我们对特发性肺纤维化发病机制的了解。
Semin Respir Crit Care Med. 2016 Jun;37(3):358-67. doi: 10.1055/s-0036-1580693. Epub 2016 May 27.
5
Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review.肺纤维化的分子机制及其向肺癌的进展：综述。
Int J Mol Sci. 2019 Mar 22;20(6):1461. doi: 10.3390/ijms20061461.
6
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.基于美国保险索赔数据的非特发性肺纤维化进行性纤维化性间质性肺疾病患者的医疗资源利用和费用。
Adv Ther. 2020 Jul;37(7):3292-3298. doi: 10.1007/s12325-020-01380-4. Epub 2020 May 21.
7
Pulmonary fibrosis, part II: state-of-the-art patient management.特发性肺纤维化，第二部分：患者管理的最新进展。
Expert Rev Respir Med. 2017 May;11(5):361-376. doi: 10.1080/17476348.2017.1312347. Epub 2017 Apr 13.
8
Advances in the treatment of idiopathic pulmonary fibrosis.特发性肺纤维化的治疗进展
Expert Opin Emerg Drugs. 2015;20(4):537-52. doi: 10.1517/14728214.2015.1102886. Epub 2015 Dec 2.
9
Idiopathic pulmonary fibrosis.特发性肺纤维化。
Expert Rev Respir Med. 2007 Dec;1(3):377-89. doi: 10.1586/17476348.1.3.377.
10
Treatment of idiopathic pulmonary fibrosis: is there anything new?特发性肺纤维化的治疗：有什么新进展吗？
Respirology. 2005 Jun;10(3):284-9. doi: 10.1111/j.1440-1843.2005.00712.x.
引用本文的文献
1
Role of inflammation-related genes as prognostic biomarkers and mechanistic implications in idiopathic pulmonary fibrosis.炎症相关基因作为特发性肺纤维化预后生物标志物的作用及其机制意义
Front Genet. 2025 Jun 18;16:1602588. doi: 10.3389/fgene.2025.1602588. eCollection 2025.
2
Mechanisms on How Matricellular Microenvironments Sustain Idiopathic Pulmonary Fibrosis.基质细胞微环境维持特发性肺纤维化的机制
Int J Mol Sci. 2025 Jun 4;26(11):5393. doi: 10.3390/ijms26115393.
3
Stage-Dependent Fibrotic Gene Profiling of WISP1-Mediated Fibrogenesis in Human Fibroblasts.人成纤维细胞中WISP1介导的纤维化形成的阶段依赖性纤维化基因谱分析
Cells. 2024 Dec 5;13(23):2005. doi: 10.3390/cells13232005.
4
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.尼达尼布基于患者档案的特发性肺纤维化患者管理
Pulm Ther. 2024 Dec;10(4):377-409. doi: 10.1007/s41030-024-00271-1. Epub 2024 Sep 28.
5
An overview of CCN4 (WISP1) role in human diseases.CCN4（WISP1）在人类疾病中的作用概述。
J Transl Med. 2024 Jun 27;22(1):601. doi: 10.1186/s12967-024-05364-8.
6
Molecular Mechanisms Responsible for the Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Lung Fibrosis.间充质干细胞衍生外泌体治疗肺纤维化的治疗潜力的分子机制
Int J Mol Sci. 2024 Apr 16;25(8):4378. doi: 10.3390/ijms25084378.
7
Airway basal cell‑derived exosomes suppress epithelial‑mesenchymal transition of lung cells by inhibiting the expression of ANO1.气道基底细胞衍生的外泌体通过抑制ANO1的表达来抑制肺细胞的上皮-间质转化。
Exp Ther Med. 2024 Mar 21;27(5):219. doi: 10.3892/etm.2024.12507. eCollection 2024 May.
8
Role and targeting of the AGC kinase family in pulmonary fibrosis (Review).AGC激酶家族在肺纤维化中的作用及靶向治疗（综述）
Exp Ther Med. 2024 Mar 8;27(5):190. doi: 10.3892/etm.2024.12478. eCollection 2024 May.
9
GRADE-ADOLOPMENT of clinical practice guidelines and creation of clinical pathways for the primary care management of chronic respiratory conditions in Pakistan.巴基斯坦基层医疗管理慢性呼吸系统疾病的临床实践指南的制定和临床路径的创建。
BMC Pulm Med. 2023 Apr 17;23(1):123. doi: 10.1186/s12890-023-02409-4.
10
Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19.激酶抑制剂作为治疗新冠病毒病的潜在治疗药物
Front Pharmacol. 2022 Apr 4;13:806568. doi: 10.3389/fphar.2022.806568. eCollection 2022.
本文引用的文献
1
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.系统评价和荟萃分析吡非尼酮、尼达尼布和贝伐珠单抗治疗特发性肺纤维化。
Ann Pharmacother. 2021 Jun;55(6):723-731. doi: 10.1177/1060028020964451. Epub 2020 Oct 15.
2
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.吡非尼酮联合乙酰半胱氨酸吸入治疗特发性肺纤维化：一项随机试验。
Eur Respir J. 2021 Jan 5;57(1). doi: 10.1183/13993003.00348-2020. Print 2021 Jan.
3
COUNTERPOINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? No.反驳观点：每位特发性肺纤维化患者都应被转诊进行移植评估吗？不应该。
Chest. 2020 Jun;157(6):1413-1414. doi: 10.1016/j.chest.2019.12.031.
4
Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).尼达尼布和西地那非治疗特发性肺纤维化合并右心功能障碍患者：一项双盲随机临床试验（INSTAGE）的预先设定亚组分析
Am J Respir Crit Care Med. 2019 Dec 15;200(12):1505-1512. doi: 10.1164/rccm.201903-0488OC.
5
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.吡非尼酮治疗更为严重的特发性肺纤维化患者的疗效。
Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2.
6
Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis.随机、双盲、安慰剂对照的奥美拉唑治疗特发性肺纤维化的初步临床试验。
Thorax. 2019 Apr;74(4):346-353. doi: 10.1136/thoraxjnl-2018-212102. Epub 2019 Jan 4.
7
Single Versus Bilateral Lung Transplantation for Idiopathic Pulmonary Fibrosis in the Lung Allocation Score Era.肺分配评分时代特发性肺纤维化的单肺与双肺移植比较。
J Surg Res. 2019 Feb;234:84-95. doi: 10.1016/j.jss.2018.08.054. Epub 2018 Oct 5.
8
Oxygen therapy for acutely ill medical patients: a clinical practice guideline.急性病内科患者的氧疗：临床实践指南
BMJ. 2018 Oct 24;363:k4169. doi: 10.1136/bmj.k4169.
9
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
Respir Res. 2018 Oct 19;19(1):203. doi: 10.1186/s12931-018-0907-8.
10
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.尼达尼布联合西地那非治疗特发性肺纤维化患者
N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15.
Zotero 插件